To the Editor: We report a case of successful renal sympathetic denervation (RSD) treatment for resistant hypertension in a patient with a single kidney.1-3 RSD is performed via femoral arterial access, using a radiofrequency ablation catheter to deliver energy to the renal artery wall. When delivering RSD to a single kidney, potential renal artery vascular complications can have a significant negative impact on a patient’s renal function, compared with patients with two functioning kidneys.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multi-centre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281.
- 2. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (the Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909.
- 3. Palmer SC, Judkins C, Williams PD, Whitbourn RJ. Renal sympathetic nerve denervation for the treatment of resistant hypertension. Med J Aust 2013; 199: 160-162. <MJA full text>
- 4. Dorr O, Hamm C, Nef HM. Single-side renal sympathetic denervation in a hypertensive patient with a single kidney. Am J Kidney Dis 2013; 61: 1042-1043.
Robert Whitbourn has received institutional grants and honoraria from Medtronic.